Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

ALS Untangled does not endorse Acuscope for slowing ALS progression

Original source

AcuscopeALSUntangled · 6 March 2017 (opens in a new tab)

ALS Untangled reviewed Acuscope, a treatment device, and found no clear evidence that it slows, stops or reverses amyotrophic lateral sclerosis (ALS). The review described one person with primary lateral sclerosis and one person with ALS whose progression measurements changed slightly during treatment, but said these changes could reflect natural variation rather than Acuscope.

Why this matters

People with ALS or primary lateral sclerosis should not consider these observations proof that Acuscope changes disease progression. ALS Untangled said the device appears reasonably safe, but its usefulness and mechanism remain unclear, so the review does not endorse it for slowing, stopping or reversing ALS.

Limitations and context

This is an independent expert review, not a controlled clinical trial. It discusses observations from only two people, and the review says natural disease variation makes the treatment effect unclear.

Summarised by Compass 10 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?